Skip to main content
Annexon, Inc. logo

Annexon, Inc. — Investor Relations & Filings

Ticker · ANNX ISIN · US03589W1027 US Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2020-07-20 Regulatory Filings
Country US United States of America
Listing US ANNX

About Annexon, Inc.

https://annexonbio.com/

Annexon, Inc. is a clinical-stage biopharmaceutical company developing a new class of complement medicines. The company's therapeutic approach is centered on inhibiting C1q, the initiating molecule of the classical complement pathway. By blocking C1q at the start of this immune cascade, Annexon aims to prevent the inflammation and tissue damage that drive a range of diseases. Its pipeline is focused on developing treatments for classical complement-mediated disorders affecting the body, brain, and eye, which include autoimmune, neurodegenerative, and ophthalmic conditions.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a correspondence letter from legal counsel responding to comment letters from the SEC staff regarding a Registration Statement on Form S-1 filed by Annexon, Inc. It discusses amendments to the Form S-1, responses to SEC comments on business disclosures, accounting policies, and stock compensation. The document is not a financial report itself but a regulatory filing related to the registration process for an IPO. It does not contain financial statements or detailed financial analysis but is a communication with the SEC about the registration statement. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2020-07-20 English
S-1/A
Capital/Financing Update Classification · 100% confidence The document is an S-1/A Registration Statement Amendment No. 1 filed with the U.S. Securities and Exchange Commission (SEC) under the Securities Act of 1933. It is a preliminary prospectus for an initial public offering (IPO) of common stock by Annexon, Inc. The document includes detailed information about the company, the offering, risk factors, use of proceeds, capitalization, management, and financial data. This type of filing is a registration statement used to register securities for public sale and is not a financial report like an annual or quarterly report, nor is it an earnings release or other types of filings listed. The S-1/A is a capital markets filing related to fundraising and securities issuance. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, consistent with a capital raising filing.
2020-07-20 English
Regulatory Filings 2020
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Due to the lack of identifiable information and the inability to determine the nature of the document, it cannot be classified into any specific filing category. According to the rules, when a document does not neatly fit into any category, it should be classified as a Regulatory Filing (RNS) as a fallback category.
2020-07-16 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a letter from a law firm to the SEC regarding a Registration Statement on Form S-1 filed by Annexon, Inc. It discusses proposed disclosure language related to a beneficial conversion feature for Series D redeemable convertible preferred stock. The letter is dated July 16, 2020, and mentions an anticipated amended Registration Statement filing on July 20, 2020. The content is focused on regulatory correspondence and disclosure language for a registration statement, not the registration statement itself or a financial report. The document length is 4571 characters, which is relatively short and consistent with a correspondence or regulatory filing rather than a full report. There is no financial data or comprehensive report content, only a discussion of disclosure language and regulatory compliance. Therefore, this document fits best under Regulatory Filings (RNS), which covers general regulatory announcements and correspondence with the SEC that do not fit other categories.
2020-07-16 English
Regulatory Filings 2020
Regulatory Filings
2020-07-15 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a detailed letter addressed to the SEC staff regarding the accounting treatment for stock-based compensation related to Annexon, Inc.'s Registration Statement on Form S-1 for an IPO. It discusses valuation methodologies, stock option grants, and fair value determinations over multiple dates. The document references the Registration Statement on Form S-1, which is a filing related to securities registration for an IPO, and includes detailed financial and accounting information relevant to the IPO process. It is not a full annual or quarterly report, nor is it an earnings release or a proxy statement. It is also not a simple announcement or certification but contains substantive financial and accounting discussion. The document is a supplemental letter providing detailed information on stock-based compensation accounting for the Registration Statement, which is a regulatory filing related to securities registration. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a detailed regulatory submission that does not fit into other specific categories like Annual Report or Earnings Release.
2020-07-14 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.